On Friday, Idera Pharmaceuticals Inc (NASDAQ:IDRA)’s shares declined -1.49% to $2.65.
Idera Pharmaceuticals, Inc. (IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, declared that it has appointed Mark J. Casey as Senior Vice President, General Counsel and Secretary of the Board of Directors.
Vincent J. Milano, Chief Executive Officer of Idera Pharmaceuticals stated, “Mark’s experience and acumen are perfect matches for Idera and we look forward to the immediate positive impact he will make to our growing team. Importantly, Mark fits incredibly well into the corporate culture we are fostering at Idera that will continue to drive us to delivering therapies for patients suffering from life-threatening diseases whose needs are presently unmet.
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for oncology and rare diseases in the United States. It uses two proprietary drug discovery technology platforms to design and develop drug candidates, counting toll-like receptor targeting technology and gene silencing oligonucleotide (GSO) technology.
Karyopharm Therapeutics Inc (NASDAQ:KPTI)’s shares dropped -5.43% to $12.02.
Karyopharm Therapeutics Inc. (KPTI), a clinical-stage pharmaceutical company, recently stated financial results for the second quarter 2015 and commented on recent accomplishments and clinical development plans for selinexor, its lead product candidate.
Michael G. Kauffman, MD, PhD, Chief Executive Officer of Karyopharm stated that Important data describing the clinical benefit of selinexor across multiple solid and hematologic malignancies was presented during the quarter, counting single agent anti-tumor activity and durable disease control in patients with recurrent glioblastoma, advanced sarcomas, ovarian and endometrial cancers. They also presented survival data in patients with relapsed/refractory diffuse large B-cell lymphoma treated with selinexor, together with combination data of selinexor with chemotherapy in patients with heavily pretreated acute myeloid leukemia.
Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The companys lead drug candidate, Selinexor, a novel selective inhibitor of nuclear export (SINE) compounds that specifically blocks XPO1 cargo binding is in Phase II clinical trials in patients with heavily pretreated relapsed and/or refractory hematological and solid tumor malignancies.
At the end of Friday’s trade, KKR & Co. L.P. (NYSE:KKR)‘s shares surged 0.53% to $22.86.
JBF Industries Ltd. (“JBF”), a leading manufacturer of polyester value-chain products, has signed a definitive agreement with global investment firm KKR under which KKR will invest US$150 million into JBF Group, an entity that comprises JBF’s international auxiliaries.
A portion of the proceeds will be used by KKR to acquire a 20% stake in JBF, listed on the BSE Ltd. and National Stock Exchange of India. The remaining proceeds will be invested into zero-coupon convertible preference shares with 14.5% voting rights in JBF Global Pte. Limited, Singapore, an unlisted partner. KKR will primarily make its investment from the KKR Special Situations Fund II.
JBF Group manufactures polyester value-chain products ranging from polyester chips, polyester yarn and films which are used in the fast-moving consumer goods, textile and packaging industries. JBF Group is one of the leading global players in the polyester segment, with six manufacturing facilities across India, Bahrain, Belgium and the United Arab Emirates.
KKR & Co. L.P. is a private equity and real estate investment firm specializing in direct and fund of fund investments. It specializes in acquisitions, leveraged buyouts, administration buyouts, credit special situations, growth equity, mature, mezzanine, distressed, and middle market investments. The firm considers investments in all industries with a focus on technology and hardware, energy and infrastructure, real estate, services industry with a focus on business services, intelligence, industry-leading franchises and companies in natural resource, containers and packaging, agriculture, airports, ports, forestry, electric utilities, textiles, apparel and luxury goods, household durables, digital media, insurance, brokerage houses, non-durable goods distribution, supermarket retailing, grocery stores, food, beverage, and tobacco, hospitals, entertainment venues and production companies, publishing, printing services, capital goods, financial services, specialized finance, pipelines, and renewable energy.
TD Ameritrade Holding Corp. (NYSE:AMTD), ended its Friday’s trading session with 0.89% gain, and closed at $36.47.
Although Americans surveyed say providing monetary support to a family member is not a financial struggle, many also maintain high debt levels and have delayed major life milestones to provide this financial assistance. TD Ameritrade’s 2015 Financial Support survey explores the struggle Americans feel towards assisting a family member in need while still in debt themselves, and reveals key differences between Generation X and Baby Boomers.1
The Real Cost of Financial Support
- One in five Americans (22 percent) provide financial support to a parent and/or an adult child (“Financial Supporters”).
- Over the past year, Financial Supporters have given $12,000 of support on average – that’s an estimated $630 billion from the US economy.2
- Few report that providing this support is causing them great financial hardship: only 22 percent say they needed to use their savings to provide financial assist while 30 percent made small sacrifices and lived more frugally.
- However, Financial Supporters hold almost $100,000 in debt on average: $22,000 in unpaid credit card balances, personal lines of credit, or personal or student loans, and $75,000 in mortgage debt.
TD Ameritrade Holding Corporation provides securities brokerage services and related technology-based financial services to retail investors, traders, and independent registered investment advisors (RIAs) in the United States. Its products and services comprise tdameritrade.com, a Web platform for self-directed retail investors; Trade Architect, a Web-based platform that enables active investors and traders identify opportunities and stay informed; thinkorswim, a desktop platform for trading; and TD Ameritrade Mobile, which allows on-the-go investors and traders to trade and monitor accounts from Web-enabled mobile devices.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
